Popular Articles

AEterna Zentaris To Report Data From Safety Study Of Phase 3 Program In Benign Prostatic Hyperplasia With Cetrorelix Ahead Of Schedule
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone.
generic viagra online
The Journal "Foot & Ankle Specialist" Accepted In Medline
Foot & Ankle Specialist (FAS), published by SAGE, has been accepted for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM), containing more than 16 million journal article citations.
News of the day
John Kufuor Leads Effort To Fight Global Hunger Among Schoolchildren
The former Ghanaian president, John Kofi Agyekum Kufuor, has
Public Health

News From The June Issue Of CHEST

PULMONARY HYPERTENSION: A CASE OF MISTAKEN IDENTITY? New research shows that patients who are diagnosed with pulmonary arterial hypertension (PAH) but fail to respond to targeted therapies may actually have a condition known as pulmonary veno-occlusive disease (PVOD), a subtype of PAH. Australian researchers reviewed 14 cases of clinically diagnosed PAH who had failed medical therapy and found that 12 patients (86 percent) had PVOD and 2 patients (14 percent) had PAH only. Although there were no significant differences in clinical presentations between patients with PVOD and PAH only, there were considerable differences in the vessel pathologic findings and pathophysiology between the two conditions. Researchers speculate that these differences may be the reason why some patients with PAH do not respond to standard PAH therapy. The researchers conclude that further research is needed to determine if PVOD should be considered an individual type of PAH or remain a PAH subtype. The study is published in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians. OVERCOMING BARRIERS TO PAIN MANAGEMENT IN THE ICU A new article underscores the many complexities and challenges associated with managing pain in the critically ill patient. Although the complex conditions presented by the critically ill patient provide significant obstacles, the authors discuss additional barriers to optimal pain management, including outdated clinical practices and faulty systems. The authors also present a number of structured approaches that have been shown to be successful in improving pain treatment in the critically ill patient, as well as future directions for pain management in the ICU. The article is published in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians. URINALYSIS MAY REVEAL SEVERITY OF BREATHING DISORDER IN CHILDREN New research suggests that the urine concentration of lipid mediators may determine the severity of sleep-disordered breathing (SDB) in children. Cysteinyl leukotrienes (CysLTs), lipid mediators associated with inflammatory conditions such as asthma, have been found in high concentrations in the tonsil tissue of children with SDB. Researchers from Greece speculated that high CysLTs concentrations found in urine also could indicate severity of SDB in children. The team measured morning urine concentrations in 19 children with moderate-to-severe SDB, 29 children with mild SDB, 26 children with primary snoring, and 18 control subjects. Results showed that children with moderate-to-severe SDB had higher CysLTs levels than the other groups. Results also showed that urine levels of CysLTs, tonsillar size, and BMI were significant predictors of obstructive apnea-hypopnea index. The report is published in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians. Jennifer Stawarz American College of Chest Physicians


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):